Age-Related Macular Degeneration (AMD) Market
Age-Related Macular Degeneration (AMD) Market Overview 2024-2034
The global age-related macular degeneration (AMD) market is poised for significant growth, with an estimated valuation of US$ 12.28 million in 2024, projected to reach US$ 23.19 million by 2034. This expansion reflects an improved CAGR of 8% over the forecast period, driven by advancements in healthcare technologies and an aging global population.
Key Market Insights
| Attribute | 2024 Estimated Value | 2034 Projected Value | CAGR (2024-2034) |
| Market Value | US$ 12.28 million | US$ 23.19 million | 8% |
| North America Market Share | 50.6% | – | – |
| Europe CAGR | 7.8% | – | – |
Drivers of Market Growth
- Increasing Aging Population:
- By 2030, 1 in 6 people worldwide will be aged 60 or older, significantly driving demand for AMD treatments.
- Advancements in Treatment Options:
- New therapies such as anti-VEGF drugs, intravitreal injections, and gene therapy are enhancing treatment efficacy.
- Rising Awareness of Eye Health:
- Global campaigns and educational initiatives are raising awareness about early detection and management of AMD.
- Improved Healthcare Infrastructure:
- Expanding healthcare facilities and investments in ophthalmology are boosting market potential, particularly in emerging economies.
Segment Analysis
By Product Type:
- Anti-VEGF Drugs
- Laser Therapy Devices
- Vitamins and Dietary Supplements
By Disease Type:
- Wet AMD
- Dry AMD
By Distribution Channel:
- Hospital Pharmacies
- Specialty Pharmacies
- Online Pharmacies
| Segment | Market Share (%) | CAGR (2024-2034) |
| Wet AMD | 60% | 8.5% |
| Dry AMD | 40% | 7.5% |
Geographic Insights
| Region | Market Share (2024) | CAGR (2024-2034) |
| North America | 50.6% | 7.8% |
| Europe | 27% | 7.5% |
| Asia-Pacific | 15% | 9% |
- North America leads due to high prevalence rates and robust healthcare systems.
- Asia-Pacific shows the fastest growth, driven by an aging population and increasing access to healthcare.
Competitive Landscape
Prominent players in the AMD market include:
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Pfizer Inc.
Recent Developments:
- In 2024, Regeneron announced a new clinical trial for a long-acting anti-VEGF formulation.
- Novartis AG secured FDA approval for a new intravitreal injection targeting wet AMD.
Frequently Asked Questions
Q1: What is the projected value of the AMD market by 2034? The market is expected to reach US$ 23.19 million by 2034.
Q2: Which region holds the largest market share? North America, with a market share of 50.6%, leads the global AMD market.
Q3: What is the primary driver of AMD market growth? An aging population and advancements in treatment technologies are key growth drivers.
Call to Action
Take action now! Contact us today to access the full report and propel your business forward. Our advisory services provide in-depth insights into established and emerging players, enabling you to make informed strategic decisions.